2016
The I.M. Rosenzweig Junior Investigator Award Winners
The I.M. Rosenzweig Junior Investigator Award was established to encourage researchers to maintain and enhance their interest in PF research during the early stages of their academic career.
-
Vinicio de Jesus Perez, MD
Stanford University
Proposal Title: “HH-10: A novel therapeutic for idiopathic pulmonary fibrosis”
This proposal is funded by the NYC Run-Walk-Hike for Pulmonary Fibrosis.
Dr. Vinicio de Jesus Perez received his MD from the University of Puerto Rico Medical School and completed an internal medicine residency at Massachusetts General Hospital. He subsequently trained in pulmonary and critical care medicine in Denver, followed by postdoctoral research training at Stanford University, where he currently serves as assistant professor of medicine. His current research focuses on understanding the genetic and molecular mechanisms of pulmonary hypertension (PH), idiopathic pulmonary fibrosis (IPF) and tuberous sclerosis/LAM. He is principal investigator of a research program dedicated to identifying new therapeutic approaches to treat these conditions. As a medical professional belonging to a minority group, Dr. de Jesus Perez is involved in academic endeavors seeking to improve access of care for patients with disadvantageous ethnic backgrounds and promote diversity in medicine. -
Koji Sakamoto, MD, PhD
Nagoya University, Japan
Proposal Title: “The role of LincRNA FENDRR as a novel regulator of myofibroblast differentiation in idiopathic pulmonary fibrosis”
This proposal is funded by the Jenny H. Krauss and Otto F. Krauss Charitable Foundation Trust, in memory of Stephen N. Dirks
Dr. Sakamoto is currently an assistant professor in the Department of Respiratory Medicine at Nagoya University Graduate School of Medicine. After several years of clinical service in one of leading center for pulmonary fibrosis patients in the country, he earned his PhD, and subsequently finished postdoctoral training at Yale University. Currently
His research interests include dissecting unveiled epigenetic mechanisms of lung fibrogenesis by implementing high-throughput analytic methodology. In particular, he has been interested in characterizing the pathogenic role of long non-coding RNAs (lncRNAs) as epigenetic disease regulators, and seeking the potential of lncRNAs as novel therapeutic targets. Besides his research activities in fibrogenesis biology, he has also established specialized clinic for pulmonary fibrosis patients to conduct clinical studies.
The Albert Rose Established Investigator Award Winners
Created to allow established investigators to explore novel, innovative areas of research, the Albert Rose Established Investigator Award provides critical support to the development of new projects, and enables the investigator to pursue additional funding through the National Institutes of Health or other agencies. Two $50,000 grants are awarded per annual cycle, disbursed over a two-year period.